Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.